secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001193125-24-074706
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Intellia terminates Factor IX co-development agreement with Regeneron; retains milestone/royalty rights under LCA
--------------------------------------------------------------------------------

- On March 19, 2024, Intellia gave notice to Regeneron to exit the Factor IX Co-Development and Co-Funding Agreement, effective after 180 days.
- Intellia will no longer share 35% of development costs or receive 35% of profits for Factor IX gene editing products upon termination.
- Under the existing License and Collaboration Agreement (LCA), Intellia remains eligible for up to $320M in milestones and high-single to low-teen royalties.
- Other collaboration programs with Regeneron under the LCA are unaffected by this termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/0001193125-24-074706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/d17601d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-074706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer